GlassScriptPhysician profile
Wendy K Stevens
NPI 1043200082
$383.94
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $11.13 · 2022: $133.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.91 | 2019-2022 | |
| Cranial Technologies, INC | $47.92 | 2019-2022 | |
| Corium, LLC | $42.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.30 | 2019 | |
| Sanofi Pasteur INC. | $29.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $27.69 | 2019 | |
| Vertical Pharmaceuticals, LLC | $23.71 | 2019 | |
| Merck Sharp & Dohme LLC | $22.28 | 2019-2020 | |
| Genentech USA, INC. | $19.29 | 2019 | |
| Tris Pharma INC | $18.54 | 2022 | |
| Neos Therapeutics, LP | $15.84 | 2022 | |
| Kaleo, INC. | $15.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.